CATX:NYSEMKT, Perspective Therapeutics, Inc.
CATX stock overview
Perspective Therapeutics, Inc. (CATX:NYSEMKT) closed at $1.25 on October 26, 2026,
down 22.67% on the day.
The stock trades 79.8% below its 52-week high of $6.16
and 11.7% above its 52-week low of $1.12.
Over the past year, it lost 46.2%.
Perspective Therapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $1.25
- Day change
- -22.67%
- Volume
- 8,421,094
- Average volume
- 1,677,721
- Market cap
- 142M+
- 52-week range
- $1.12 – $6.16
- 50-day average
- $2.78
- 200-day average
- $3.58
Price action over the past year
In 252 trading sessions since October 23, 2025, CATX closed higher on 113 days (45%).
Its best day was January 29, 2026 (+66.41%) and its worst was October 23, 2026 (-28.76%).
The stock moved 10% or more in a single session 11 times.
Recent signals
CATX news
-
Oct 23, 2026:
Perspective Therapeutics Posts 72% 18-Month PFS in VMT-α-NET Study Update
-
Oct 23, 2026:
Perspective's [212Pb]Bamzireotide Navoxetan (VMT-a-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
-
Oct 23, 2026:
Perspective's [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs
-
Oct 9, 2026:
Strength Seen in Profound Medical (PROF): Can Its 21.7% Jump Turn into More Strength?
-
Oct 8, 2026:
Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors
-
Oct 7, 2026:
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-a-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
-
Oct 7, 2026:
Perspective Therapeutics Announces Acceptance of [212Pb]VMT-α-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium
-
Oct 2, 2026:
Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
About Perspective Therapeutics, Inc.
Isoray Inc offers is a medical technology company. The company designs and develops personalized brachytherapy products that provide a more cost-effective cancer treatment. It is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. Isoray derives most of its revenue from the United States of America.
Similar stocks
Find more stocks like CATX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.